Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree
Wow! So many big trades going through!
You will be considered a pattern day trader if you trade four or more times in five business days and your day-trading activities are greater than six percent of your total trading activity for that same five-day period.
True! I have to believe Tierney is making headway on securing funding. Possibly inside news is spreading.
You know!
Looking strong!
Nice steady rise today! Hopefully Tierney made quite an impression at the conference today.
I agree with that attitude! Tierney is going to secure funding! This is definitely going to be a great year for BioPharmX!
BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference
SAN JOSE, Calif., March 18, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced presentations at multiple upcoming investor conferences.
President and CEO Dr. David S. Tierney will present the latest company overview at:
The 31st Annual ROTH Conference on Monday, March 18 at 8:30am Pacific Time in Laguna Niguel, CA.
The Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:00pm Eastern Time in New York, NY.
BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results
SAN JOSE, Calif., March 14, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter and year ended January 31, 2019.
Fiscal Year 2019 and Recent Business Highlights
Initiated and completed enrollment for its Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea. The randomized, double-blind, vehicle-controlled study enrolled 207 subjects with moderate-to-severe papulopustular rosacea across 12 sites and is evaluating the safety and efficacy of once daily application of BPX-04, a 1% minocycline gel, versus a vehicle control over a 12-week treatment period. The study's primary endpoint is the mean change in the number of facial inflammatory lesions from baseline to week 12. The company anticipates announcing topline efficacy and safety data from the study in July 2019.
Strengthened the management team with the appointment of Dr. David S. Tierney as president and chief executive officer. Dr. Tierney has nearly 30 years of executive leadership experience and a proven track record of success with three NDA approvals, one PMA approval and three successful company exits.
Bolstered the board of directors with the appointments of Dr. David S. Tierney and Dr. R. Todd Plott. Dr. Plott is a board-certified dermatologist with 30 years' experience, 16 years of which were spent working as a research physician in the pharmaceutical industry. He has been involved in nine prescription drug development programs that received approval from the U.S. Food and Drug Administration for products including SOLODYNâ„¢, ZIANAâ„¢ and NORITATEâ„¢.
Reduced operating costs by reducing its workforce by approximately 40%, discontinuing non-core development programs, divesting its women's health business and relocating its headquarters to a lower-cost location in San Jose, California.
Received notice that the U.S. Patent and Trademark Office awarded patent protection for its novel tetracycline-class topical drug composition. This patent protects tetracycline-class antibiotics carried by BioPharmX's HyantX topical delivery system, which, for the first time, stabilizes and fully solubilizes these drugs to make them effective in a topical formulation.
Received notice that the U.S. Food and Drug Administration waived its requirement for a dermal carcinogenicity study for BPX-01, eliminating several years of non-clinical research normally required for FDA review.
Entered into agreements with certain stockholders to amend certain existing warrants to reduce the exercise price per share and to issue new warrants, in exchange for the stockholders' agreement to exercise their existing warrants for cash, resulting in net proceeds to the company of $3.6 million.
Requested and was granted an extension from the NYSE American until April 30, 2019 to regain compliance with the continued listing standards related to the company's low stock price. Additionally, the company has until September 24, 2019 to regain compliance with certain NYSE American continued listing standards related to the stockholders' equity requirements. As previously stated, maintaining compliance with listing standards is of paramount importance and the company is working with NYSE American to restore full compliance.
"We met our primary objectives this quarter in completing the enrollment of our BPX-04 Phase 2b clinical trial, bolstering our board of directors and reducing our operating costs," said Dr. Tierney, BioPharmX CEO. "The company has and will continue to make the necessary changes to position the company for long-term success and we look forward to informing our shareholders as we make further progress."
Fourth Quarter Financial Results
For the fourth quarter ended January 31, 2019, total operating expenses were $3.2 million, compared with total operating expenses of $3.6 million in the prior fiscal year's fourth quarter.
Net loss for the quarter ended January 31, 2019 was $4.1 million, or $0.02 per share, compared with a net loss of $3.8 million, or $0.03 per share, during the prior fiscal year's fourth quarter.
Excluding stock-based compensation expense, a charge related to the modification of certain warrants and the impact of the change in the fair value of the warrant liability, non-GAAP net loss for the quarter ended January 31, 2019 was $2.9 million, or $0.01 per share. During the fourth quarter of the prior fiscal year, the comparable non-GAAP net loss was $3.4 million, or $0.03 per share.
Fiscal Year 2019 Financial Results
Total operating expenses for the fiscal year ended January 31, 2019 were $16.5 million, compared with $16.7 million in the prior fiscal year. The decrease resulted primarily from lower headcount-related and consulting expenses, partially offset by higher clinical trial and product development costs related to BPX-04.
Net loss for the fiscal year was $17.3 million, or $0.09 per share, compared with a net loss of $16.6 million, or $0.19 per share, during the prior fiscal year.
Excluding stock-based compensation expense, a charge related to the modification of certain warrants and the impact of the change in the fair value of the warrant liability, non-GAAP net loss for the fiscal year ended January 31, 2019 was $14.4 million, or $0.07 per share. In the prior fiscal year, the comparable non-GAAP net loss was $15.0 million, or $0.17 per share.
Cash and cash equivalents, as of January 31, 2019, were $3.1 million.
BioPharmX also disclosed, in its Annual Report on Form 10-K for the fiscal year ended January 31, 2019, filed March 14, 2019 with the Securities and Exchange Commission, that its audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern paragraph. See further discussion in footnote 2 to BioPharmX's consolidated financial statements included in its Annual Report on Form 10-K. This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires separate public announcement of the receipt of an audit opinion containing a going concern paragraph.
I like the recent news on this one!
Nice! Still getting the word out!
Looking for another run here soon! Been steady climbing!
Why a Potential IVST Breakout Deserves a Close Look
IVST recently partnered with one of the fastest growing private companies in the country to help drive its energy business
IVST is making real money, with trailing revs already coming in at $2.9M.
IVST has less than 12M shares on the float, suggesting strong upside potential could result from just a small influx of new interest
IVST is currently building toward a potential breakout of a bullish flag pattern
IVST also just signed a letter of intent to purchase 100% of a revenue-producing building materials supply company
https://www.wallstreetpr.com/why-a-potential-ivst-breakout-deserves-a-close-look-41318
Topical Minocycline Formulations: Evaluation and Comparison of Dermal Uptake Efficacy
* Our data suggests the ability to deliver minocycline directly to the epidermis and pilosebaceous
* topical hydrophilic minocycline gel formulations demonstrated more than 2 to 3-fold drug penetration compared to topical lipophilic minocycline formulations of equivalent concentration
* data further suggest that the topical hydrophilic minocycline gel formulation is superior to the topical lipophilic minocycline formulation in delivering minocycline to the pilosebaceous unit where P. acnes typically reside
https://www.sciencedirect.com/science/article/pii/S2590156719300234?via%3Dihub
Chart warming up to another run? Looks like it's been creeping up.
Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will present a corporate overview and business update at the Barclays Global Healthcare Conference 2019, taking place March 12-14 at the Loews Miami Beach Hotel in Miami, Florida.
Barclays Global Healthcare Conference 2019 Date: Wednesday, March 13 Time: 3:20pm Eastern Time Location: Loews Miami Beach Hotel Webcast: https://cc.talkpoint.com/barc002/031219a_as/?entity=33_GY5VHDJ About Foamix
Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will present a corporate overview and business update at the Cowen and Company 39 Annual Health Care Conference, taking place March 11-13 at the Boston Marriott Copley Place hotel in Boston, Massachusetts.
Cowen and Company 39 Annual Health Care Conference Date: Tuesday, March 12 Time: 10:40am Eastern Time Location: Boston Marriott Copley Place Webcast: http://wsw.com/webcast/cowen52/fomx/ About Foamix
They need to secure funding by way of partner or venture capitalist. There's still costly trials ahead and it's all up to Tierney to find the best way to continue on without too much dilution.
We have to see what Tierney is going to work out. There's still a lot of buzz around BioPharmX product development and so there is definitely value in what they have created and what they are working on.
Risk vs Reward! Understanding the cost of these trials and development can give you an understanding of why these type of companies sell off in the hundreds of millions. The question here is, how much is BioPharmX and their delivery system worth? Once you have a guess on that figure, divide it by the outstanding shares and now you have an idea of a reachable share price if a buyout occurred.
Where the price is sitting now and for those holding a low average, it would be a fantastic rate of return on your investment! That's why I'm here! Risk vs Reward!
GLTY
BioPharmX is an R&D company, so I think they are wanting to sell their HYANTX and BPX designs over merging.
Definitely been rough for longs, but let's see what this new CEO can pull off! He has an excellent resume!
GLTY
It's actually .20 for 30 day average AMEX/NYSE. You can Google that with BPMX added to your search for confirmation.
Well, IMO it looks like Tierney has a different plan to get the stock price back in compliance otherwise we would have been provided an RS date like AKER's did on their second extension. You can also search and find other companies that received a second extension that included a RS date in the agreement. Ours doesn't say that so, hope!???
You mean the RS they could have gone forward with on this second extension from the SEC? Interesting that they didn't provide a plan for an RS although the SEC gave out another extension without a planned date. Looks like the company sees things happening differently.
On sale of the company, yes and beyond. On news regarding progress, I don't believe so. I don't have the numbers with me but I believe if it makes it close to a dollar on terrific news, it will get stopped around the .90 range, and that's if if has enough strength to break .37, and we're pretty far away from that resistance (.37).
Funding has to come from somewhere and most likely will be through offering shares. More shares, harder to climb up the ladder. Great product, but my long hold is for the buyout.
Amazing product and pipeline! Just need to secure funding and know what's the game plan after BPMX-04 P2b.
In November 2018, the company reduced its operating costs by executing a 33% reduction in workforce and discontinuing non-core development programs. As part of this more focused strategy, the company divested its molecular iodine technology, including the dietary supplement product, VI2OLET, thereby allowing the company to focus on its dermatology product candidates.
So your a bit caught up...
https://www.prnewswire.com/news-releases/biopharmx-reports-third-quarter-2019-financial-results-300761396.html
Yep, too many fleas to shake off at these levels. Maybe a few news announcement's to build momentum then release something substantial. We'll see!
It's coming! Building up!!
BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea
Company anticipates announcing topline efficacy and safety results in July 2019
SAN JOSE, Calif., March 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has completed enrollment of its Phase 2b clinical trial with BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
"This is an important milestone for our rosacea program and we look forward to reporting topline results from the study later this year," said David Tierney, BioPharmX CEO. "Unlike currently available therapies which may further irritate a patient's already sensitive skin, BPX-04—which utilizes our proprietary HyantX topical delivery system—was designed to improve the bioavailability of solubilized minocycline and enable a more targeted delivery to minimize irritation. Based on results from earlier studies, we believe that BPX-04 may provide an effective treatment for rosacea while minimizing the unwanted adverse effects associated with oral forms of antibiotics, as well as the tolerability limitations of topical treatments, thereby addressing an unmet need for 16 million patients in the US alone."
Rosacea is a chronic dermatologic condition characterized by redness, stinging and inflammatory lesions primarily on the face. The biology of rosacea remains unclear, however it is thought to be an inflammatory disorder that involves immune responses and microorganisms. Rosacea is estimated to affect more than 16 million people in the United States alone, according to the National Rosacea Society. Current treatment options, while limited, include oral antibiotics, anti-parasitics, azelaic acids and alpha-A agonists.
The randomized, double-blind, vehicle-controlled study enrolled 207 subjects with moderate-to-severe papulopustular rosacea. The multicenter study is evaluating the safety and efficacy of once daily application of BPX-04, a 1% minocycline gel, versus a vehicle control over a 12-week treatment period. The study's primary endpoint is the mean change in the number of facial inflammatory lesions of rosacea from baseline to week 12.
Sure! Nothing wrong with dreaming big!
Cowen Analysts Give Foamix Pharmaceuticals (FOMX) a $30.00 Price Target
https://www.google.com/amp/s/pressoracle.com/news/2019/03/03/cowen-analysts-give-foamix-pharmaceuticals-fomx-a-30-00-price-target.html/amp
Definitely speculation as to what the company has in mind for their plans. I like the fact that they didn't state that they were choosing to go with a reverse split in this recent press release. That makes me think that they have a plan to get the stock price up without reversing.
I believe the company might use this extension time to get a little closer to the trial closing date. They also may be waiting for warrants to expire (is what I read elsewhere), all while looking to secure funding for P3 of either BPX-01 or BPX-04 or both. One thing that is for sure, we're going to know more within two months.
I expect David Tierney is seeking the best deal for investors and the company and must have a plan otherwise he would have chosen a reverse split date.
GLTY and hope you have a prosperous year!
Here's a link to follow.
I think we'll be hearing something in regards to funding before we hear about any study results.
Estimated Primary Completion Date: May 17, 2019
Estimated Study Completion Date: August 17, 2019
https://clinicaltrials.gov/ct2/show/NCT03667222?term=biopharmx&rank=1
I agree!!
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on February 25, 2019 from the NYSE American LLC (the "NYSE American") that granted the Company an extension from February 27, 2019 to April 30, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock.
https://mma.prnewswire.com/media/510652/BioPharmX_Corporation_Logo.jpg
On August 27, 2018, the Company initially received a de ficiency letter from NYSE American stating that the Company was not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide because the Company's common stock had been selling for a low price per share for a substantial period of time. The NYSE American staff determined that the Company's continued listing is predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time.
The Company's common stock will continue to be listed and traded on NYSE American during the extended cure period, subject to the Company's compliance with NYSE American's other applicable continued listing standards. The letter does not affect the Company's business op erations or its Securities and Exchange Commission reporting requirements.
Long-term there's hope for Foamix. I think they are going to have great gains but unfortunately it's a slow process. I think that they will have some milestones this year that could start reversing the downtrend.
Yes, I know about dragging out the timeline! Seems like forever to get this stuff to market!
Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CAR-T Therapy
https://globenewswire.com/news-release/2019/02/26/1742414/0/en/Avalon-GloboCare-Announces-Filing-of-Provisional-Patent-Applications-for-AVA-101-a-Novel-Transposon-Based-Multi-Targeted-CAR-T-Therapy.html
Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it will participate in the American Academy of Dermatology (AAD) Annual Meeting to take place March 1 - 5, 2019 at the Walter E. Washington Convention Center, in Washington D.C.
Clinical data on the Company's late stage clinical development candidates, FMX101 for moderate to severe acne, and FMX103 for papulopustular rosacea, are expected to be covered in oral presentations by leading clinical dermatologists during the meeting. The Company will also host a medical affairs booth, with medical affairs staff on-site to answer qu estions on its clinical data as well as on its proprietary foam technology.
The American Academy of Dermatology is one of the largest, non-partisan professional organizations of dermatologists in the world. Each year, AAD convenes an annual meeting to discuss the latest advances and trending topics in dermatology in more than 300 educational sessions across various tracks. Last year's AAD meeting drew more than 18,750 attendees.
"This is a great opportunity for the medical community to hear some of the most recent clinical study data on our late stage candidates for acne and rosacea," said David Domzalski, C EO of Foamix. "We submitted our New Drug Application (NDA) for FMX101 to the US FDA late last year, with an anticipated PDUFA date in Q4 2019, and are planning to submit another NDA for FMX103 in rosacea in mid-2019. The combined total body of clinical data supporting these candidates, including positive results from Phase 3 trials, suggests that they have the potential to address significant unmet needs in their respective dermatology indications. Pending regulatory approvals by FDA, Foamix could be in a position to commercialize FMX101 in early 2020 followed by FMX103 in the second half of 2020."
Medical Affairs Booth:
Booth # 4301
Open: March 1 - 2 from 10am to 5pm; March 3 from 10am to 3pm
Relevant Presentations and Details:
Session: New Emerging Therapies (S003)
Date and Tim e: Friday March, 1 9:48 a.m., Eastern Time
Location: Ballroom C
Presenter: Dr. Diane Bersen
Presentation: New and Emerging Therapies for Acne and Rosacea
Session: Acne Boot Camp (F005)
Date and Time: Friday March 1, 10:30 a.m., Eastern Time
Location: Ballroom B
Presenter: Dr. Leon Kircik
Presentation: New and Emerging Treatments for Acne
Session: Acne and Rosacea (S043)
Location: Room 207A
Date and Time: Sunday March 3, 1:23 p.m., Eastern Time
Presentation: Acne: What's new and What's on the Horizon?
Date and Time: Sunday March 3, 2:30 p.m., Eastern Time
Presenter Dr. Hilary Baldwin
Presentation Rosacea: What's New?
Well that worked out nicely! Maybe your "gltu" helped. I'm out. Enjoy your time here!
Looks like the CEO is trying to get some attention on the stock! Could be a good sign! Keeping watch on this one!
https://globenewswire.com/news-release/2019/02/22/1740267/0/en/Interviews-with-CEO-Denis-Corin-of-Q-BioMed-and-CEO-George-Nikopoulos-of-Mannin-Research.html
Plott, Ronald Todd New director, just awarded options to buy, of 418,000 shares.
He can exercise them after 3/1/19.